Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Adults - 18 - 64
  • Florida
  • Tallahassee


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com




Results

Post your clinical trial on JoinClinicalTrials.com
Hot

Post your clinical trial on JoinClinicalTrials.com


Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

Results 1 - 1 of 1
  • <<
  • <
  • 1
  • >
  • >>

  • Computerized Intervention for Loneliness
    NCT03839966
    Condition:   Loneliness
    Interventions:   Behavioral: Interpretation Bias Modification for Loneliness;   Behavioral: Healthy Habits Psychoeducation and Relaxation
    Sponsor:   Florida State University
    Recruiting
  • The Role of microRNA-210 in Regulating Oxidative Stress in Patients With PAD
    NCT04089943
    Conditions:   Peripheral Arterial Disease;   Vascular Diseases, Peripheral;   Arterial Occlusive Diseases;   Atherosclerosis
    Interventions:   Procedure: Revascularization operation;   Other: Control group
    Sponsors:   Florida State University;   National Institute on Aging (NIA)
    Recruiting
  • Iron Absorption and Exercise
    NCT04079322
    Conditions:   Iron-deficiency;   Iron Deficiency Anemia
    Intervention:   Other: Meal
    Sponsor:   Florida State University
    Recruiting
  • Family Genetics Health Education and Healthy Behaviors
    NCT01498276
    Conditions:   Diabetes;   Cancer;   Heart Disease
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting
  • This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia
    NCT03859973
    Condition:   Schizophrenia
    Interventions:   Drug: BI 425809;   Drug: Placebo
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
    NCT02907177
    Condition:   Multiple Sclerosis
    Interventions:   Drug: Ponesimod;   Other: Placebo
    Sponsor:   Actelion
    Recruiting
  • Post-Approval 'Real Conditions of Use' Study
    NCT02555280
    Condition:   Spinal Stenosis
    Interventions:   Device: coflex® Interlaminar Technology;   Procedure: Decompression
    Sponsors:   Paradigm Spine;   Musculoskeletal Clinical Regulatory Advisers
    Recruiting
  • Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor
    NCT03977467
    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: Atezolizumab;   Other: Chemotherapy (Arm A Only)
    Sponsors:   SCRI Development Innovations, LLC;   Genentech, Inc.
    Recruiting
  • Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC
    NCT03952325
    Condition:   Breast Cancer
    Interventions:   Drug: Tesetaxel;   Drug: Nivolumab;   Drug: Pembrolizumab;   Drug: Atezolizumab
    Sponsor:   Odonate Therapeutics, Inc.
    Recruiting
  • An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer
    NCT03915951
    Condition:   Non-small Cell Lung Cancer
    Interventions:   Drug: encorafenib;   Drug: binimetinib
    Sponsor:   Array BioPharma
    Recruiting
  • Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer
    NCT03786094
    Conditions:   Metastatic Breast Cancer;   Locally Recurrent Breast Cancer
    Interventions:   Drug: Eribulin;   Drug: Balixafortide
    Sponsor:   Polyphor Ltd.
    Recruiting
  • Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation
    NCT03781063
    Condition:   Locally Advanced or Metastatic Breast Cancer
    Interventions:   Drug: Lasofoxifene;   Drug: Fulvestrant
    Sponsors:   Sermonix Pharmaceuticals LLC;   Linical Accelovance Group
    Recruiting
  • Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.
    NCT03697304
    Condition:   Neoplasm Metastasis
    Interventions:   Drug: BI 754091;   Drug: BI 754111;   Drug: BI 891065
    Sponsor:   Boehringer Ingelheim
    Recruiting
  • A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
    NCT03197935
    Condition:   Triple-negative Breast Cancer
    Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody;   Drug: Placebo;   Drug: Nab-paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Filgrastim;   Drug: Pegfilgrastim
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
    NCT03919994
    Condition:   Schizophrenia
    Intervention:  
    Sponsor:   Alkermes, Inc.
    Recruiting
  • Study of Nivolumab Versus Placebo in Participants With High-Risk Breast Cancer
    NCT04109066
    Condition:   Breast Cancer
    Interventions:   Biological: nivolumab;   Drug: paclitaxel (PTX);   Other: nivolumab placebo;   Drug: anthracycline;   Drug: cyclophosphamide;   Drug: Endocrine Therapy;   Procedure: Surgery
    Sponsor:   Bristol-Myers Squibb
    Recruiting
  • This Study Will Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab
    NCT04108156
    Condition:   Diabetic Macular Edema
    Interventions:   Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab;   Drug: Intravitreal Ranibizumab 0.5 mg Injection
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
    NCT04031885
    Condition:   Metastatic Breast Cancer
    Interventions:   Drug: Abemaciclib;   Drug: Fulvestrant;   Drug: Standard Chemotherapy
    Sponsor:   Eli Lilly and Company
    Recruiting
  • A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
    NCT03972709
    Conditions:   Macular Degeneration, Age-Related;   Geographic Atrophy
    Interventions:   Drug: RO7171009;   Drug: Sham Control
    Sponsor:   Genentech, Inc.
    Recruiting
  • A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD
    NCT03953079
    Condition:   Neovascular Age-Related Macular Degeneration
    Interventions:   Drug: Drug: GB-102;   Drug: Aflibercept
    Sponsor:   Graybug Vision
    Recruiting
  • Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous NSCLC
    NCT03906071
    Condition:   Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Interventions:   Biological: Nivolumab;   Drug: Sitravatinib;   Drug: Docetaxel
    Sponsors:   Mirati Therapeutics Inc.;   Bristol-Myers Squibb
    Recruiting
  • TRILUMINATE Pivotal Trial
    NCT03904147
    Condition:   Tricuspid Regurgitation
    Intervention:   Device: Tricuspid valve repair
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
    NCT03869684
    Condition:   Age-related Macular Degeneration
    Interventions:   Drug: MT-0814;   Drug: Placebo
    Sponsors:   Senju Pharmaceutical Co., Ltd.;   PPD
    Recruiting
  • Florida Pancreas Collaborative Next Generation Biobank
    NCT03851133
    Conditions:   Pancreatic Cancer;   Cancer Cachexia
    Interventions:   Other: Blood Sample Collection;   Other: Tumor Sample collection;   Other: Data Collection
    Sponsor:   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting
  • A Study Assessing AR-13503 Implant Alone and in Combination With Aflibercept in Subjects With nAMD or DME
    NCT03835884
    Conditions:   Neovascular Age-related Macular Degeneration;   Diabetic Macular Edema
    Interventions:   Drug: AR-13503 Implant Low Dose;   Drug: AR-13503 Implant High Dose;   Drug: Aflibercept;   Other: Sham
    Sponsor:   Aerie Pharmaceuticals
    Recruiting
  • XIENCE 28 USA Study
    NCT03815175
    Conditions:   Bleeding Disorder;   Ischemic Stroke;   Hemorrhagic Stroke;   Hematological Diseases;   Thrombocytopenia;   Coagulation Disorder;   Anemia;   Renal Insufficiency;   Coronary Artery Disease
    Interventions:   Device: XIENCE;   Drug: DAPT (aspirin and/or P2Y12 receptor inhibitor)
    Sponsor:   Abbott Medical Devices
    Recruiting
  • A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer
    NCT03701334
    Condition:   Early Breast Cancer
    Interventions:   Drug: Ribociclib;   Other: Endocrine Therapy
    Sponsors:   Novartis Pharmaceuticals;   Translational Research in Oncology
    Recruiting
  • The INSPIRE-ASP UTI Trial
    NCT03697096
    Condition:   Urinary Tract Infection (UTI)
    Interventions:   Other: Routine Care;   Other: INSPIRE CPOE Smart Prompt
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting
  • The INSPIRE-ASP PNA Trial
    NCT03697070
    Condition:   Pneumonia
    Interventions:   Other: INSPIRE CPOE Smart Prompt;   Other: Routine Care
    Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America Healthcare (HCA);   University of California, Irvine;   University of Massachusetts, Amherst;   Brigham and Women's Hospital;   Centers for Disease Control and Prevention
    Recruiting
  • GB001 in Adult Subjects With Moderate to Severe Asthma
    NCT03683576
    Condition:   Asthma
    Interventions:   Drug: GB001;   Drug: Placebo Oral Tablet
    Sponsor:   GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.
    Recruiting
  • Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions
    NCT03682536
    Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: Luspatercept;   Drug: Epoetin alfa
    Sponsors:   Celgene;   Acceleron Pharma, Inc.
    Recruiting
  • Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
    NCT03650114
    Condition:   Relapsing Multiple Sclerosis
    Interventions:   Biological: Ofatumumab;   Biological: Tetanus toxoid (TT) containing vaccine (Td, Tdap);   Biological: 13-valent pneumococcal conjugate vaccine (13-PCV);   Biological: 23-valent pneumococcal polysaccharide vaccine (23-PPV);   Biological: Seasonal Quadrivalent influenza vaccine;   Biological: Keyhole limpet hemocyanin (KLH) neo-antigen
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
    NCT03525600
    Condition:   Geographic Atrophy
    Interventions:   Drug: APL-2;   Other: Sham Procedure
    Sponsor:   Apellis Pharmaceuticals, Inc.
    Recruiting
  • Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A
    NCT03447769
    Condition:   Non-Small Cell Lung Cancer
    Interventions:   Drug: Canakinumab;   Drug: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation
    NCT03433274
    Conditions:   Mitral Regurgitation;   Mitral Insufficiency;   Mitral Valve Insufficiency;   Cardiovascular Diseases;   Valve Disease, Heart;   Heart Valve Diseases;   Functional Mitral Regurgitation;   Degenerative Mitral Valve Disease
    Interventions:   Device: Tendyne Mitral Valve System;   Device: MitraClip System
    Sponsor:   Abbott Medical Devices
    Recruiting
  • Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
    NCT03373045
    Condition:   Asthma
    Intervention:  
    Sponsors:   AstraZeneca;   Parexel;   MedImmune LLC
    Recruiting
  • Corticosteroid Lumbar Epidural Analgesia for Radiculopathy
    NCT03372161
    Condition:   Lumbosacral Radicular Pain
    Interventions:   Drug: SP-102;   Drug: Placebo
    Sponsors:   Semnur Pharmaceuticals, Inc.;   Worldwide Clinical Trials;   Scilex Pharmaceuticals, Inc.
    Recruiting
  • WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement
    NCT03173534
    Conditions:   Atrial Fibrillation;   Aortic Valve Stenosis
    Interventions:   Device: WATCHMAN;   Device: TAVR
    Sponsors:   Samir Kapadia;   Boston Scientific Corporation;   The Cleveland Clinic
    Recruiting
  • Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
    NCT03137771
    Conditions:   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
    Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy (3D-CRT);   Drug: Docetaxel;   Drug: Gemcitabine;   Radiation: Intensity-Modulated Radiation Therapy (IMRT);   Drug: Pemetrexed Disodium;   Radiation: Stereotactic Body Radiation Therapy (SBRT);   Drug: Erlotinib Hydrochloride;   Drug: Pembrolizumab
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial
    NCT03108456
    Conditions:   Coronary Artery Disease;   Ischemic Heart Disease;   Non ST Segment Elevation Myocardial Infarction
    Interventions:   Device: Orbital Atherectomy;   Device: Balloon
    Sponsors:   Cardiovascular Systems Inc;   Cardiovascular Research Foundation, New York
    Recruiting
  • REDUCE LAP-HF TRIAL II
    NCT03088033
    Condition:   Heart Failure
    Interventions:   Device: IASD System II implant;   Other: intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)
    Sponsor:   Corvia Medical
    Recruiting
  • Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
    NCT02954874
    Conditions:   Invasive Breast Carcinoma;   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Patient Observation;   Biological: Pembrolizumab;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
    NCT02947347
    Condition:   Treatment Naive Follicular Lymphoma
    Interventions:   Drug: ibrutinib;   Drug: placebo to match ibrutinib;   Drug: rituximab
    Sponsor:   Pharmacyclics LLC.
    Recruiting
  • Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
    NCT02943785
    Condition:   Atrial Fibrillation
    Interventions:   Drug: Edoxaban-based Regimen;   Drug: VKA-based Regimen
    Sponsors:   Daiichi Sankyo, Inc.;   Chiltern International Inc.
    Recruiting
  • Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP
    NCT02923726
    Condition:   Sudden Cardiac Death
    Interventions:   Device: Arm 1 (ATP+Shock);   Device: Arm 2 (shock only)
    Sponsors:   Boston Scientific Corporation;   ICON plc
    Recruiting
  • Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)
    NCT02923193
    Condition:   Peripheral Arterial Disease
    Interventions:   Device: Shockwave Lithoplasty® Peripheral Lithoplasty System;   Drug: Medtronic IN.PACT (DCB)
    Sponsor:   Shockwave Medical, Inc.
    Recruiting
  • Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
    NCT02793583
    Conditions:   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Zone Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: TGR-1202 + Ublituximab;   Drug: TGR-1202;   Drug: TGR-1202 + Ublituximab + Bendamustine
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • Breast Cancer WEight Loss Study (BWEL Study)
    NCT02750826
    Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP);   Canadian Cancer Trials Group
    Recruiting
  • Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
    NCT02488967
    Conditions:   Breast Adenocarcinoma;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIC Breast Cancer;   Triple-Negative Breast Carcinoma
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel
    Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
    Recruiting
  • SPYRAL HTN-ON MED Study
    NCT02439775
    Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
    Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
    Sponsor:   Medtronic Vascular
    Recruiting
  • SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
    NCT02439749
    Conditions:   Hypertension;   Vascular Diseases;   Cardiovascular Diseases
    Interventions:   Device: Symplicity Spyral™ multi-electrode renal denervation system;   Procedure: Sham Procedure
    Sponsor:   Medtronic Vascular
    Recruiting
  • Web Based Orthopaedic Sports Medicine Registry
    NCT01191151
    Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
    Intervention:  
    Sponsor:   Arthrex, Inc.
    Recruiting
  • A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
    NCT01848561
    Condition:   Ulcerative Colitis (UC)
    Intervention:  
    Sponsor:   AbbVie
    Recruiting
  • Connect® MDS/AML Disease Registry
    NCT01688011
    Conditions:   Myelodysplastic Syndromes;   Acute Myeloid Leukemia
    Intervention:  
    Sponsor:   Celgene
    Recruiting
  • A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines
    NCT03580369
    Condition:   Chronic Spontaneous Urticaria
    Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC